98,189 results match your criteria Pancreatic Cancer


Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy.

Eur J Med Chem 2019 Mar 9;170:28-44. Epub 2019 Mar 9.

State Key Laboratory of Analytical Chemistry for Life Science, Collaborative Innovation Centre of Chemistry for Life Sciences, Jiangsu Key Laboratory of Advanced Organic Materials, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023, PR China. Electronic address:

Pancreatic cancer is one of the most deadly neoplasm with a 5-year survival rate of less than 6% owing to its remarkable tolerance to nutrient starvation, and new drugs and treatment strategies are urgently needed. During a project aiming at discovery of anticancer agents, we performed a structure modification on polycyclic polyprenylated acylphloroglucinols (PPAPs) skeleton, and discovered that PPAP rearranged to a tetrahydroquinolin-2(1H)-one feature. Here, series of tetrahydroquinolin-2(1H)-one derivatives were designed, synthesized and evaluated against a highly metastatic human pancreatic cancer cell line (PANC-1), and the structure-activity relationship was also discussed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2019.03.013DOI Listing

3 T MR perfusion of solid pancreatic lesions using dynamic contrast-enhanced DISCO sequence: Usefulness of qualitative and quantitative analyses in a pilot study.

Magn Reson Imaging 2019 Mar 13. Epub 2019 Mar 13.

Diagnostic and Interventional Radiology, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy. Electronic address:

Purpose: To assess the usefulness of qualitative and quantitative analyses of pancreatic focal diseases by using the dynamic contrast-enhanced Differential Subsampling with Cartesian Ordering (DISCO) sequence at 3 T MR device.

Materials And Methods: Ten patients without pancreatic diseases and twenty-five patients with pathologically confirmed pancreatic focal disease (ductal adenocarcinoma, n = 14; endocrine tumour, n = 8; focal chronic pancreatitis, n = 3), underwent MRI by 3 T-device. Multiphasic contrast-enhanced MR perfusion, consisting of a 3D axial navigator, based free-breathing T1-weighted DISCO sequence, was repeated for 5 min. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mri.2019.03.001DOI Listing

Techniques for splenic vein reconstruction after pancreaticoduodenectomy with portal vein resection for pancreatic cancer.

HPB (Oxford) 2019 Mar 13. Epub 2019 Mar 13.

Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan. Electronic address:

Background: Pancreaticoduodenectomy (PD) with splenic vein (SV) ligation may result in sinistral portal hypertension (SPH). The aim of this study was to compare the outcomes of various types of SV reconstruction to prevent SPH and to define the optimal reconstruction method.

Methods: This study included patients who underwent PD with SV resection and reconstruction for pancreatic cancer between December 2013 and June 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hpb.2019.01.017DOI Listing

Modeling Pancreatic Cancer through Somatic Editing with AAV.

Trends Mol Med 2019 Mar 13. Epub 2019 Mar 13.

Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA. Electronic address:

Genetically engineered mouse models have revolutionized the study of pancreatic cancer, but have several technical and practical limitations. A new adeno-associated virus (AAV)-driven somatic genome-editing model of pancreatic ductal adenocarcinoma reported by Ideno et al. (Lab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molmed.2019.02.012DOI Listing

Pancreatic cancer – What's next?

Presse Med 2019 Mar 13. Epub 2019 Mar 13.

University of Verona Hospital Trust, The Pancreas Institute, Unit of General and Pancreatic Surgery, Verona, Italy.

This chapter focuses on the most recent advantages in the medical treatment of localized pancreatic cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2019.02.031DOI Listing

Pancreatic cancer is still waiting for the big leap forward.

Presse Med 2019 Mar 13. Epub 2019 Mar 13.

AP-HP, hôpital Beaujon, department of hepato-pancreato-biliary surgery, pôle des maladies de l'appareil digestif (PMAD), 92110 Clichy, France; Université Paris Diderot, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2019.02.013DOI Listing

Epidemiology and burden of pancreatic cancer.

Presse Med 2019 Mar 13. Epub 2019 Mar 13.

Unit of Clinical Epidemiology, IEO, European Institute of Oncology IRCCS, Milan, Italy. Electronic address:

Pancreatic cancer, although infrequent, has a very poor prognosis, making it currently the fourth common causes of cancer mortality in most developed countries including the European Union (EU). Its incidence varies across regions, which suggests that lifestyle factors play an important role in its etiology, although part of the variation could be ascribed to difference in diagnostic and coding practices. Because pancreatic cancer is strongly age-dependent, increasing population longevity and ageing will lead to an increase of the global burden of pancreatic cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2019.02.030DOI Listing

Pancreatic cancer: Best supportive care.

Presse Med 2019 Mar 13. Epub 2019 Mar 13.

Paris 7 Diderot University, Centre de recherche sur l'inflammation, Inserm UMR1149, 100, boulevard du Général-Leclerc, 92110 Clichy La Garenne, France; Curie Institute, Medical Oncology Department, Versailles Saint Quentin University, 35, rue Dailly, 92210 Saint-Cloud, France. Electronic address:

Palliative and supportive care holds a major place in pancreatic ductal adenocarcinoma (PDAC) management. It aims to prevent and reduce symptoms and hospital admissions, while ensuring optimal health-related quality of life (HRQoL), which has been reported to be correlated with overall survival in PDAC. Best supportive care includes non-specific treatment of pain, anxiety and depression, chemotherapy-related toxicities, as well as thromboembolic disease treatment and prevention in high-risk patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07554982193008
Publisher Site
http://dx.doi.org/10.1016/j.lpm.2019.02.032DOI Listing
March 2019
1 Read

Practice patterns of VTE chemoprophylaxis after discharge following hepatic and pancreatic resections for cancer: A survey of hepatopancreatobiliary surgeons.

J Thromb Thrombolysis 2019 Mar 15. Epub 2019 Mar 15.

National Institutes of Health, 10 Center Drive, Room 4W-3740, Bethesda, MD, 20892, USA.

Patients with hepatopancreatobiliary (HPB) malignancies undergoing resection are prone to venous thromboembolism (VTE), and current guidelines recommend up to 28 days of chemoprophylaxis after major surgery. We sought to determine the practice patterns among HPB surgeons for use of chemoprophylaxis after discharge. A survey on VTE chemoprophylaxis after oncologic HPB operations was distributed to attending surgeons at the 18 HPB fellowship training programs in the United States and Canada. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01834-9DOI Listing
March 2019
1 Read

Laparoscopic left lateral sectionectomy for a patient with right-sided ligamentum teres.

Surg Case Rep 2019 Mar 15;5(1):43. Epub 2019 Mar 15.

Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.

Background: A right-sided ligamentum teres (RSLT) is a rare congenital anomaly in which the fetal umbilical vein is connected to the right paramedian trunk. RSLT creates difficulty in liver resection with respect to decision-making regarding the resection line, deviation of the vasculobiliary architecture. We report a case in which laparoscopic left lateral sectionectomy (LLLS) was performed to treat colorectal liver metastasis (CRLM) in a patient with RSLT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-019-0601-1DOI Listing

Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.

Surg Today 2019 Mar 15. Epub 2019 Mar 15.

Department of Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.

The aim of the study was to evaluate the effect of neoadjuvant therapy on long-term survival in patients with resectable and borderline resectable pancreatic cancer. A meta-analysis was conducted using the reported randomized, controlled trials and retrospective studies using an intention-to-treat analysis to compare upfront surgery and neoadjuvant therapy in resectable or borderline resectable pancreatic cancer patients. Six comparative studies consisting of two randomized, controlled trials and four retrospective studies were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00595-019-01786-wDOI Listing

Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer.

Surgery 2019 Mar 12. Epub 2019 Mar 12.

Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Background: Lymph node metastases from papillary thyroid cancer is believed to disseminate sequentially, first to the central neck and later to the lateral neck. Skip metastases of papillary thyroid cancer, however, are defined as lateral lymph node metastasis without central lymph node metastasis. The aim of this study was to investigate the risk factors for skip metastases and lateral lymph node metastasis of papillary thyroid cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.surg.2019.01.025DOI Listing

Detection of KRAS G12D point mutation level by anchor-like DNA electrochemical biosensor.

Authors:
Ni Zeng Juan Xiang

Talanta 2019 Jun 31;198:111-117. Epub 2019 Jan 31.

Hunan Provincial Key Laboratory of Efficient and Clean Utilization of Manganese Resources, Central South University, Changsha 410083, Hunan, PR China; College of Chemistry and Chemical Engineering, Central South University, Changsha 410083, Hunan, PR China. Electronic address:

KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer. Here, we developed a novel anchor-like DNA (alDNA) electrochemical sensor for the detection of KRAS point mutation level (the concentration ratio of the specific KRAS point mutant DNA (M-DNA) to the total DNA (t-DNA) of both mutant and wild-type DNAs carrying the same allele). Compared to those conventional ligation-based DNA sensors, the proposed alDNA sensor achieved the one-step capture of both wild-type and mutant DNA, and the subsequent detection on one chip, which effectively decreased systematic errors from the uncertain differences on the interfacial structural and microenvironmental changes, improved the detection accuracy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.talanta.2019.01.105DOI Listing

Implanted vascular access device related deep vein thrombosis in oncology patients: A prospective cohort study.

Thromb Res 2019 Mar 6;177:117-121. Epub 2019 Mar 6.

The Ottawa Hospital Research Institute, 725 Parkdale Ave, Ottawa, Ontario K1Y 4E9, Canada; The Ottawa Hospital, Box 710, 501 Smyth Rd., Ottawa, Ontario K1H 8L6, Canada. Electronic address:

Background: Implanted vascular access devices (IVADs) have significantly improved the management of cancer patients. These patients are at an increased risk of venous thromboembolism and IVADs are a known risk factor. We sought to assess the incidence of IVAD-related upper extremity deep vein thrombosis (IVAD-related UEDVT) associated with BioFlo® IVADs (Angiodynamics, Inc. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00493848193007
Publisher Site
http://dx.doi.org/10.1016/j.thromres.2019.02.033DOI Listing
March 2019
2 Reads

Transformable nanotherapeutics enabled by ICG: towards enhanced tumor penetration under NIR light irradiation.

Nanoscale 2019 Mar 15. Epub 2019 Mar 15.

Department of Nanomedicine and Biopharmaceuticals, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China. and National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China and Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, Huazhong University of Science and Technology, Wuhan, 430074, China.

Tumor penetration is the bottleneck for current cancer nanomedicine, limiting the ultimate antitumor efficacy in the clinic. Herein, by exploiting the well-known instability of indocyanine green (ICG), we report the preparation of near infrared (NIR) light responsive nanoparticles (NP) for enhanced tumor penetration. ICG crosslinks hydroxyethyl starch (HES) and doxorubicin (DOX) conjugates (HES-SS-DOX) via noncovalent interactions, facilitating the formation of ICG@HES-SS-DOX NP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c9nr01049aDOI Listing

Quantifying the oligomeric state of hZIP4 on the surface of cells.

Biochemistry 2019 Mar 15. Epub 2019 Mar 15.

The human (h) zinc transporter ZIP4 is expressed on the plasma membrane and functions to increase cytosolic zinc levels. Mutations in hZIP4 cause the disease Acrodermatitis Enteropathica (AE). Dysfunction in the regulation of hZIP4 has also been indicated in solid tissue cancers, including pancreatic and prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.biochem.9b00131DOI Listing

Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers.

Front Oncol 2019 27;9:115. Epub 2019 Feb 27.

Department of Computer Sciences, University of Turin, Turin, Italy.

Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not eligible for a curative surgical resection. For this reason there is an urgent need for personalized therapies. PDA is the result of complex interactions between tumor molecular profile and metabolites produced by its microenvironment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400843PMC
February 2019

Diagnostic Significance of Serum IgG Galactosylation in CA19-9-Negative Pancreatic Carcinoma Patients.

Front Oncol 2019 27;9:114. Epub 2019 Feb 27.

NHC Key Laboratory of Glycoconjugates Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.

Although Carbohydrate antigen 19-9 (CA19-9) is considered clinically useful and informative for pancreatic carcinoma (PC), false positive results, and false negative results have restricted its clinical use. Especially missed or delayed diagnosis of PC patients with negative CA19-9 value limited the utility. To improve prognosis of PC patients, the discovery of reliable biomarkers to assist CA19-9 is desired. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402387PMC
February 2019

Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques.

Nat Biomed Eng 2018 Nov 13;2(11):810-821. Epub 2018 Aug 13.

Division of Transplantation, Department of Surgery, University of Illinois at Chicago, 840 South Wood Street, Chicago, IL 60612, USA.

The transplantation of pancreatic islet cells could restore glycaemic control in patients with type-I diabetes. Microspheres for islet encapsulation have enabled long-term glycaemic control in diabetic rodent models; yet human patients transplanted with equivalent microsphere formulations have experienced only transient islet-graft function, owing to a vigorous foreign-body reaction (FBR), to pericapsular fibrotic overgrowth (PFO) and, in upright bipedal species, to the sedimentation of the microspheres within the peritoneal cavity. Here, we report the results of the testing, in non-human primate (NHP) models, of seven alginate formulations that were efficacious in rodents, including three that led to transient islet-graft function in clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41551-018-0275-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413527PMC
November 2018

An Overview of the Polymorphisms of Circadian Genes Associated With Endocrine Cancer.

Front Endocrinol (Lausanne) 2019 26;10:104. Epub 2019 Feb 26.

Genomic Medicine Department, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada, Andalusian Regional Government, PTS Granada, Granada, Spain.

A major consequence of the world industrialized lifestyle is the increasing period of unnatural light in environments during the day and artificial lighting at night. This major change disrupts endogenous homeostasis with external circadian cues, which has been associated to higher risk of diseases affecting human health, mainly cancer among others. Circadian disruption promotes tumor development and accelerate its fast progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2019.00104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401647PMC
February 2019

Sensitization and synergistic anti-cancer effects of Furanodiene identified in zebrafish models.

Sci Rep 2019 Mar 14;9(1):4541. Epub 2019 Mar 14.

State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu Province, 210009, P. R. China.

Furanodiene is a natural terpenoid isolated from Rhizoma Curcumae, a well-known Chinese medicinal herb that presents anticancer effects in various types of cancer cell lines. In this study, we have successfully established zebrafish xenografts with 5 various human cancer cell lines; and validated these models with anti-cancer drugs used clinically for treating human cancer patients. We found that Furanodiene was therapeutically effective for human JF 305 pancreatic cancer cells and MCF-7 breast cancer cells xenotranplanted into zebrafish. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-40866-2DOI Listing

Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer.

Gut 2019 Mar 14. Epub 2019 Mar 14.

Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden.

Objectives: Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic cysts that can progress to invasive pancreatic cancer. Associations between oncogenesis and oral microbiome alterations have been reported. This study aims to investigate a potential intracystic pancreatic microbiome in a pancreatic cystic neoplasm (PCN) surgery patient cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/gutjnl-2018-317458DOI Listing

.

Mol Cancer Res 2019 Mar 14. Epub 2019 Mar 14.

Department of Gastrointestinal Tract Surgery, Fukushima Medical University.

Immunotherapy against the interaction between programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) has emerged as a promising strategy for colorectal cancer (CRC) with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). The study aimed to identify microRNAs (miRNAs) that post-transcriptionally control PD-L1 expression on tumor cells and also regulate immune evasion. A comprehensive miRNA screening using The Cancer Genome Atlas (TCGA) dataset (n=260) combined with eight different miRNA target prediction programs resulted in the identification of a tumor suppressive miRNA, miR-148a-3p, as a potential negative regulator of PD-L1 expression, particularly in dMMR/MSI-H CRC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-18-0831DOI Listing

A new fast phasing method based on haplotype subtraction.

J Mol Diagn 2019 Mar 11. Epub 2019 Mar 11.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, and the Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address:

We developed a novel phasing approach, based solely on molecules and genotype frequency, and that does not rely on inference of new alleles. We initiated the project because of errors that were detected in the phased 1000 genomes data. The algorithm first combined identical genotypes into clusters and ranked them by descending frequency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2018.12.004DOI Listing

Pancreatic Neuroendocrine Tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database.

Int J Surg 2019 Mar 11. Epub 2019 Mar 11.

Department of Hepatobiliary and Pancreatic Surgery, Northern Jiangsu People's Hospital, Clinic Medical College of Yangzhou University, Yangzhou, Jiangsu, 225001, China. Electronic address:

Background: Pancreatic neuroendocrine tumours (pNETs) are a rare and heterogeneous group of tumours with an increasing incidence. Current staging criteria for pNETs remain limited and controversial. Meanwhlie, the impact of chemotherapy on overall survival has not been fully defined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijsu.2019.03.006DOI Listing

Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.

J Immunother Cancer 2019 Mar 14;7(1):75. Epub 2019 Mar 14.

State Key Laboratory for Diagnosis & Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Background: Aberrant expression of the RON receptor tyrosine kinase is a pathogenic feature and a validated drug target in various types of cancers. Currently, therapeutic antibodies targeting RON for cancer therapy are under intensive evaluation. Here we report the development and validation of a novel humanized anti-RON antibody-drug conjugate for cancer therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0525-0DOI Listing

Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis.

BMC Cancer 2019 Mar 14;19(1):232. Epub 2019 Mar 14.

Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Piazzale Scuro, 10, 37134, Verona, Italy.

Background: Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by a broad range of neoplasms to maintain telomere length, permitting uncontrolled replication during their progression. ALT has been described in different types of sarcoma, but a comprehensive analysis of its clinical significance is still lacking. Therefore, we provide here the first meta-analysis on this topic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5424-8DOI Listing

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types.

Cancers (Basel) 2019 Mar 13;11(3). Epub 2019 Mar 13.

Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.

Dysfunctional homologous recombination DNA repair (HRR), frequently due to BRCA mutations, is a determinant of sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi). In cultures of ovarian cancer cells, we have previously shown that HRR function, based upon RAD51 foci quantification, correlated with growth inhibition ex vivo induced by rucaparib (a PARPi) and 12-month survival following platinum chemotherapy. The aim of this study was to determine the feasibility of measuring HRR dysfunction (HRD) in other tumours, in order to estimate the frequency and hence wider potential of PARPi. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11030354DOI Listing

METTL3 and ALKBH5 oppositely regulate mA modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes.

Autophagy 2019 Mar 14. Epub 2019 Mar 14.

a Longju Medical Research Center; Key Laboratory of Basic Pharmacology of Ministry of Education ; Zunyi Medical University ; Zunyi , China.

N-methyladenosine (mA) mRNA modifications play critical roles in various biological processes. However, no study addresses the role of mA in macroautophagy/autophagy. Here, we show that mA modifications are increased in H/R-treated cardiomyocytes and ischemia/reperfusion (I/R)-treated mice heart. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15548627.2019.1586246DOI Listing

The novel Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces apoptosis in human breast cancer cells.

Neoplasma 2019 Mar 7. Epub 2019 Mar 7.

Department of Gastroduodenal and Pancreatic Surgery, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

Jab1 is a vital subunit of the CSN family, which is reported to be overexpressed in numerous cancer types. For the importance of Jab1/CSN5 in cancer cell proliferation and survival, it is considered as a promising therapeutic target. Thus, we evaluated the anticancer effect of a novel Jab1 inhibitor CSN5i-3 in breast cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4149/neo_2018_181016N772DOI Listing

Molecular Mechanism Exploration of Pancreatitis Based on miRNA Expression Profile.

Clin Lab 2019 Mar;65(3)

Background: Pancreatitis is a popular disease around the world, and can also lead to pancreatic cancer. Pancreatitis can be distinguished into two types, acute pancreatitis (AP) and chronic pancreatitis (CP). Every year, AP leads to approximately 275,000 new cases and is the most frequent gastrointestinal disease in American. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7754/Clin.Lab.2018.180807DOI Listing

Tumour-specific and organ-specific protein synthesis rates in patients with pancreatic cancer.

J Cachexia Sarcopenia Muscle 2019 Mar 13. Epub 2019 Mar 13.

NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.

Background: Living tissues maintain a fine balance between protein synthesis and protein breakdown rates. Animal studies indicate that protein synthesis rates are higher in organs when compared with skeletal muscle tissue. As such, organ and tumour protein synthesis could have major effects on whole-body protein metabolism in wasting disorders such as cancer cachexia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcsm.12419DOI Listing
March 2019
2 Reads

Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery.

Ann Surg Oncol 2019 Mar 13. Epub 2019 Mar 13.

Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Background: Accumulation of evidence suggests that neoadjuvant chemotherapy improves the outcomes of borderline resectable pancreatic cancer (BRPC). Gemcitabine plus nab-paclitaxel (GnP) has been widely accepted as systemic chemotherapy for unresectable pancreatic cancer and reportedly results in remarkable tumor shrinkage. This study was performed to evaluate the safety and efficacy of neoadjuvant chemotherapy using neoadjuvant GnP for BRPC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-019-07309-8DOI Listing

SIRT1 promotes GLUT1 expression and bladder cancer progression via regulation of glucose uptake.

Hum Cell 2019 Mar 13. Epub 2019 Mar 13.

Department of Urology Surgery, Hunan People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 410005, China.

Bladder cancer (BC) is one of the most common tumors. Metabolic reprogramming is a feature of neoplasia and tumor growth. Understanding the metabolic alterations in bladder cancer may provide new directions for bladder cancer treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13577-019-00237-5DOI Listing

Feasibility and safety of distal pancreatectomy with en bloc celiac axis resection (DP-CAR) combined with neoadjuvant therapy for borderline resectable and unresectable pancreatic body/tail cancer.

Langenbecks Arch Surg 2019 Mar 13. Epub 2019 Mar 13.

Department of General Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.

Purpose: Pancreatic body/tail cancer commonly invades the hepatic artery or celiac artery, making surgical resection difficult. Distal pancreatectomy with celiac axis resection (DP-CAR) has recently been performed to achieve curative resection of these tumors. However, the safety and efficacy remain unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00423-019-01775-0DOI Listing

Incidence of Pancreatic Adenocarcinoma in the United States from 2001 to 2015: A United States Cancer Statistics Analysis of 50 States.

Cureus 2018 Dec 28;10(12):e3796. Epub 2018 Dec 28.

Internal Medicine, Temple University, Philadelphia, USA.

Introduction Pancreatic cancer is one of the leading causes of death in both males and females in the United States. Nearly 85% of pancreatic cancer is adenocarcinoma. Given the silent disease progression of pancreatic cancer, identifying at-risk populations will help diagnose these fatal cancers as early as possible. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3796DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402725PMC
December 2018

Response to: Comment on "Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer".

Dis Markers 2019 5;2019:6287315. Epub 2019 Feb 5.

Department of Epidemiology and Health Statistics, College of Public Health, Qingdao University, Qingdao, Shandong 266021, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/6287315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379861PMC
February 2019

Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers.

Theranostics 2019 20;9(5):1490-1509. Epub 2019 Feb 20.

Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, Rostock, Germany.

Metastasis management remains a long-standing challenge. High abundance of E2F1 triggers tumor progression by developing protein-protein interactions (PPI) with coregulators that enhance its potential to activate a network of prometastatic transcriptional targets. To identify E2F1-coregulators, we integrated high-throughput Co-immunoprecipitation (IP)/mass spectometry, GST-pull-down assays, and structure modeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.29546DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401510PMC
February 2019

Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma.

Theranostics 2019 20;9(5):1417-1425. Epub 2019 Feb 20.

J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, P.O. Box 116131, Gainesville, FL 32611, USA.

Pancreatic ductal adenocarcinoma (PDAC) requires multimodal therapeutic approaches and disease monitoring for effective treatment. Liquid biopsy biomarkers, including circulating tumor cells (CTCs) and cancer stem-like cells (CSCs), hold promise for evaluating treatment response promptly and guiding therapeutic modifications. From 24 patients with metastatic PDAC (stage IV, M1) undergoing active systemic treatment, we collected 78 blood samples at different time points for CTC and CSC isolation using a microfluidic platform functionalized with antibodies against a CTC biomarker, epithelial cell adhesion molecule (EpCAM), or a CSC biomarker, CD133. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.28745DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401494PMC
February 2019

A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer.

Theranostics 2019 12;9(5):1280-1287. Epub 2019 Feb 12.

Ulm University, Department of Internal Medicine I, Albert-Einstein-Allee 23, 89081 Ulm, Germany.

The most frequent malignancy of the pancreas is the pancreatic ductal adenocarcinoma (PDAC). Despite many efforts PDAC has still a dismal prognosis. Biomarkers for early disease stage diagnosis as a prerequisite for a potentially curative treatment are still missing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.29247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401492PMC
February 2019

ZFP91 zinc finger protein expression pattern in normal tissues and cancers.

Oncol Lett 2019 Mar 23;17(3):3599-3606. Epub 2019 Jan 23.

Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznan, Poland.

Zinc finger protein 91 (ZFP91) gene has been recently acknowledged to possess oncogenic properties. To date, its expression has been examined only in a handful of human organs and cancer types. The aim of the present study was to characterize, for the first time, the ZFP91 expression pattern in a range of human tissues and cancer types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2019.9963DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396258PMC

ATAD2 is associated with malignant characteristics of pancreatic cancer cells.

Oncol Lett 2019 Mar 23;17(3):3489-3494. Epub 2019 Jan 23.

Division of Cancer Biology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.

Pancreatic cancer is one of the most aggressive human cancers and is associated with a poor prognosis. To develop a novel strategy for pancreatic cancer treatment, it is essential to elucidate the molecular mechanisms underlying the invasion and proliferation of cancer cells. ATPase family AAA domain containing protein 2 (ATAD2) is a highly conserved protein with an AAA+ domain and a bromodomain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2019.9960DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396210PMC

Primary cilia and their role in cancer.

Oncol Lett 2019 Mar 17;17(3):3041-3047. Epub 2019 Jan 17.

School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.

Primary cilia are microtubule-based organelles that are expressed on almost all mammalian cells. It has become apparent that these structures are important signaling hubs that serve crucial roles in Wnt, hedgehog, extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and Notch signaling pathways. A number of diseases have been found to involve dysfunctional primary cilia; collectively these diseases are called ciliopathies. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ol.2019.9942
Publisher Site
http://dx.doi.org/10.3892/ol.2019.9942DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396132PMC
March 2019
1 Read

miR-212 regulated by HIF-1α promotes the progression of pancreatic cancer.

Exp Ther Med 2019 Mar 29;17(3):2359-2365. Epub 2019 Jan 29.

Key Laboratory of Cancer Prevention and Therapy, Department of Anesthesia, Cancer Institute, National Clinical Research Center for Cancer, Tianjin Medical University Hospital, Tianjin 300060, P.R. China.

MicroRNA-212 (miR-212) is dysregulated in numerous tissues and cancer types and serves a role in the progression of human cancer. However, the function and mechanism of miR-212 in the development of pancreatic ductal adenocarcinoma (PDAC) remain unknown, particularly in a hypoxic microenvironment. In the present study, miR-212 expression was observed to be significantly upregulated in PDAC tissues compared with normal tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2019.7213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396010PMC

Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma.

Cancer Cell Int 2019 4;19:49. Epub 2019 Mar 4.

1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032 China.

Background: Hepatocyte nuclear factor 4α (HNF4α) is a tissue-specific transcription factor that regulates the expression of numerous genes in hepatocytes and pancreatic β cells. HNF4α has been reported to affect cell proliferation and chemoresistance in several cancers. However, the role of HNF4α in pancreatic adenocarcinoma (PDAC) has not been studied extensively and remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0767-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398265PMC

Functional polymorphisms in LncRNA HOTAIR contribute to susceptibility of pancreatic cancer.

Cancer Cell Int 2019 28;19:47. Epub 2019 Feb 28.

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Jiaxing University, No. 1882 Zhonghuan South Road, Jiaxing, 314001 Zhejiang People's Republic of China.

Background: Pancreatic cancer (PC) remains one of the most aggressive cancers worldwide. However, genetic factors underlying PC susceptibility remain largely unclear. Long noncoding RNA (lncRNA) HOX transcript antisense RNA (HOTAIR) acts as an oncogene and its genetic variation has been linked to many cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0761-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396528PMC
February 2019

Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk.

Br J Cancer 2019 Mar 14. Epub 2019 Mar 14.

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

Background: Individuals with a family history of cancer may be at increased risk of pancreatic cancer. Ashkenazi Jewish (AJ) individuals carry increased risk for pancreatic cancer and other cancer types.

Methods: We examined the association between family history of cancer, AJ heritage, and incident pancreatic cancer in 49 410 male participants of the prospective Health Professionals Follow-up Study. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0426-5
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0426-5DOI Listing
March 2019
1 Read

Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis.

Sci Rep 2019 Mar 13;9(1):4354. Epub 2019 Mar 13.

University of Strathclyde, Department of Management Science, Glasgow, G4 0QU, Scotland, United Kingdom.

Current treatment recommendations for resectable pancreatic cancer support upfront resection and adjuvant therapy. Randomized controlled trials offering comparison with the emerging neoadjuvant approach are lacking. This review aims to compare both treatment strategies for resectable pancreatic cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-40951-6DOI Listing

MicroRNA-137 reduces stemness features of pancreatic cancer cells by targeting KLF12.

J Exp Clin Cancer Res 2019 Mar 12;38(1):126. Epub 2019 Mar 12.

Guizhou Medical University, Guiyang, China.

Background: Cancer stem cells (CSCs) play an important role in the development of pancreatic cancer. We previously showed that the microRNA miR-137 is downregulated in clinical samples of pancreatic cancer, and its expression negatively regulates the proliferation and invasiveness of pancreatic cancer cells.

Methods: The stemness features of pancreatic cancer cells was detected by flow cytometry, immunofluorescence and sphere formation assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1105-3DOI Listing

Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells.

Cancer Biol Ther 2019 Mar 13:1-11. Epub 2019 Mar 13.

b Department of Biochemistry and Molecular Biology, School of Medicine , University of Maryland , Baltimore , MD , USA.

SRC and its activated form, phospho-SRC (pSRC), are aberrantly activated in pancreatic cancer and SRC represents a potential target for pancreatic cancer therapy. In this paper, we examined the inhibitory effect of dasatinib, a potent SRC inhibitor in combination with paclitaxel or gemcitabine on human and murine pancreatic cancer cell lines. The results showed that p-SRC can be highly expressed in most human and mouse pancreatic cancer cell lines compared with normal human cell lines and can be induced by paclitaxel or gemcitabine in HPAC cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2019.1579956DOI Listing